Abstract:Objective: To investigate the clinical significance of suppressor of cytokine signaling 1 (SOCS1) hypermethylation in typical myelo-proliferative neoplasms (MPNs), and to discuss the potential mechanism. Methods: Methylation specific PCR was used to detect the hypermethylation status of SOCS1 gene in bone marrow specimens from patients with typical MPNs. Granulocyte colony stimulating factor (G-CSF) was used as a chemical inducer to simulate the MPNs cells for different time, then the real-time quantitative PCR and Western blotting were applied to evaluate the expressions of SOCS1 mRNA and protein, respectively. After the demethylating agent 2-deoxyazacytidin was used to cultivate MPNs cells for different time, SOCS1 mRNA expression was detected by real-time quantitative PCR. Results: Hypermethylation of SOCS1 was detected in 27 of 100 (27.0%) cases of MPNs. The expressions of SOCS1 mRNA in the MPNs cells were significantly decreased after G-CSF intervention in the SOCS1 hypermethylation groups as compared with those in the non-methylation groups (P0.05). The expressions of SOCS1 protein in the SOCS1 hypermethylation groups from patients with MPNs were decreased, but there was no statistically significant difference as compared with normal controls (P0.05). In addition, SOCS1 mRNA expression was markedly promoted in MPNs cells after treatment with the demethylating agent as compared with the hypermethylated groups induced by G-CSF The roles of hypermethylation and demethylation of suppressor of cytokine signaling 1 gene in typical myelo-proliferative neoplasms QIN Wei, LU Hui-na, HUANG Bin-bin, XIU Bing, BO Lan-jun, GAO Qing-mei, ZHANG Wen-jun, LIANG Ai-bin Department of Hematology, Tongji Hospital, Tongji University, Shanghai 200065, China Abstract Objective: To investigate the clinical significance of suppressor of cytokine signaling 1 (SOCS1) hypermethylation in typical myelo-proliferative neoplasms (MPNs), and to discuss the potential mechanism. Methods: Methylation specific PCR was used to detect the hypermethylation status of SOCS1 gene in bone marrow specimens from patients with typical MPNs. Granulocyte colony stimulating factor (G-CSF) was used as a chemical inducer to simulate the MPNs cells for different time, then the real-time quantitative PCR and Western blotting were applied to evaluate the expressions of SOCS1 mRNA and protein, respectively. After the demethylating agent 2-deoxyazacytidin was used to cultivate MPNs cells for different time, SOCS1 mRNA expression was detected by real-time quantitative PCR. Results: Hypermethylation of SOCS1 was detected in 27 of 100 (27.0%) cases of MPNs. The expressions of SOCS1 mRNA in the MPNs cells were significantly decreased after G-CSF intervention in the SOCS1 hypermethylation groups as compared with those in the non-methylation groups (P0.05). The expressions of SOCS1 protein in the SOCS1 hypermethylation groups from patients with MPNs were decreased, but there was no statistically significant difference as compared with normal controls (P0.05). In addition, SOCS1 mRNA expression was markedly promoted in MPNs cells after treatment with the demethylating agent as compared with the hypermethylated groups induced by G-CSF (P0.05). Conclusion: Hypermethylation of SOCS1 exists in MPNs, and the hypermethylation of CpG can inhibit the expression of SOCS1 gene. After demethylation, the expression of SOCS1 gene increases in MPNs. These suggest that the SOCS1 hypermethylation may be associated with the risk of MPNs. Demethylation may become a potential therapeutic strategy for MPNs.

Study on Aberrant Methylations of SHP-1, P15 and SOCS-1 Genes in Diffuse Large B-cell Lymphoma

Study on the Aberrant Methylation of SOCS-1 Gene in Diffuse Large B-cell Lymphoma

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

Significance of Methylation State in SHP-1 Gene in B-cell Lymphoma

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

Study on Methylation of P15ink4b Gene and Its Mechanisms in Patients with Myelodysplastic Syndrome and Leukemia.

Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients

[Experimental Study of SHP-1 Promoter Methylation in Myelodysplastic Syndromes and Its Related Mechanism].

The roles of hypermethylation and demethylation of suppressor of cytokine signaling 1 gene in typical myelo-proliferative neoplasms

The Methylation of SOCS-1 Gene in Adult Acute Myeloid Leukemia

Methylation contributes to imbalance of PRDM1α/PRDM1bβ expression in diffuse large B-cell lymphoma.

Promoter Hypermethylation of PTPL1, PTPN6, DAPK, P16 and 5-Azacitidine Inhibits Growth in DLBCL.

Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm

Association between SOCS gene hypermethylation and classical myeloproliferative neoplasms

Significance of SHP-1 Expression in Benign Lesions of Lymphoid Tissues and Lymphomas

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma

Hypermethylation of SHP-1 Promoter in Patient with High-Risk Myelodysplastic Syndrome and It Predicts Poor Prognosis

A Novel Method of Microarray Quantitave Analysis of P16 CPG Island Methylation in Leukemia Cells from Patients with Hematological Malignancies.

Clinical significance of BCL2L10 expression and promoter methylation in myelodysplastic syndrome

Detection of Aberrantly Methylated Tumor Suppressor Genes in Breast Cancer Patients As a Potential Diagnostic Biomarker